# US 11,001,615 B2 · Mutated tau protein fragment and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,001,615 B2
- Document ID: US11001615B2
- Status: Granted
- Kind: B2
- Application number: 16/472,022
- Filed: 2017-12-20
- Published: 2019-10-31
- Granted: 2021-05-11
- Earliest claimed: 2016-12-21
- Assignees: Adel Inc.
- Applicants: Adel Inc.
- Inventors: Seung-Yong Yoon; Na-Young Kim; Dong-Hou Kim
- Web page: https://patentgrep.com/patent/US11001615B2

## CPC

- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A61K 39/0007: {Nervous system antigens; Prions}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/2821: Alzheimer
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a mutated tau protein fragment and a use thereof. The mutated tau protein fragment of the present invention consists of 12 amino acids and thus can easily be prepared. In addition, when the mutated tau protein fragment is injected into an individual as an antigen, a neutralizing antibody against the mutated tau protein is generated. Moreover, the mutated tau protein fragment reduces the aggregation of abnormal tau proteins. Accordingly, the mutated tau protein fragment of the present invention can be effectively used for the prevention or treatment of degenerative neurological diseases.

## Claims

### Claim 1

A vaccine comprising
an isolated modified tau protein fragment consisting of the following 12 consecutive amino acid residues:
(SEQ ID NO: 1)
Val-Gln-Ile-Ile-Asn-Lys-Lys-Leu-Asp-Leu-Ser-Asn
wherein lysine at position 6 of SEQ ID NO: 1 is acetylated, as an active ingredient; and
an adjuvant selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, an aluminum adjuvant, pluronic polyol, a polyanion, a hydrocarbon emulsion, and dinitrophenol.

### Claim 2 (depends on 1)

The vaccine of claim 1, which further comprises a carrier selected from the group consisting of lysolecithin, a peptide, oil, and keyhole limpet hemocyanin.